<?xml version="1.0" encoding="UTF-8"?>
<results title="testTrace">
 <result pre="(http://creativecommons.org/licenses/by/4.0/). Abstract As the outbreak of the new coronavirus (SARS-CoV-2)" exact="infection" post="is spreading globally, great effort is being made to"/>
 <result pre="asymptomatic or mildly symptomatic patients as well as on the" exact="testing" post="strategy adopted in different settings, which may result in"/>
 <result pre="proportion of undiagnosed cases. An accurate estimate of the overall" exact="infection" post="fatality is still very difficult to calculate. Recent estimates"/>
 <result pre="However, taking into account the ratio of asymptomatic cases support" exact="infection" post="fatality ratios hovering 0.4â€&quot;0.7% [5]. These figures are lower"/>
 <result pre="severity and mortality. As clinical and epidemiologic information on SARS-CoV-2" exact="infection" post="have increased, a better knowledge on the burden of"/>
 <result pre="immune pathology driving disease progression, may therefore provide opportunities for" exact="treatment" post="interventions and vaccine development. 2. What We Know about"/>
 <result pre="of ACE2 may facilitate or protect alveolar cells from the" exact="infection" post="is still debated [21]. Binding of the S1 subunit"/>
 <result pre="TMPRSS2 is androgen-regulated and this may be related to higher" exact="prevalence" post="of both infection and severe disease in males [22,23]."/>
 <result pre="and this may be related to higher prevalence of both" exact="infection" post="and severe disease in males [22,23]. After viral entry"/>
 <result pre="[33]. Recent findings support a primary role of endothelial cell" exact="infection" post="and resulting endotheliitis in Covid-19 pathogenesis, which may lead"/>
 <result pre="injury [31]. Endothelial injury may be due to direct viral" exact="infection" post="of endothelial cells as well as to endothelial activation"/>
 <result pre="microthrombi may be an early phenomenon directly linked to viral" exact="infection" post="rather than to the inflammatory reaction. A significant incidence"/>
 <result pre="cells, causing activation and secretion of inflammatory cytokines [38]. Direct" exact="infection" post="of lymphocytes via ACE2 binding had been previously demonstrated"/>
 <result pre="replicate in lymphocytes, and it is uncertain whether direct lymphocyte" exact="infection" post="can contribute to the lymphopenia associated with severe Covid-19."/>
 <result pre="Immune Response (Figure 1a II) The initial response to coronaviruses" exact="infection" post="by the innate immune system plays a pivotal role"/>
 <result pre="that IFN-I production in the very early phase of the" exact="infection" post="is a crucial step affecting the course of the"/>
 <result pre="administration of IFN-I protects mice from lethal infection, while delayed" exact="treatment" post="does not prevent the development of fatal pneumonia and"/>
 <result pre="Interferon Induced Transmembrane Protein 3 (IFITM3) that reduce further cell" exact="infection" post="by viral particles [53]. Of note, IFITM3 mutations have"/>
 <result pre="to blood and spleen contributing to the spread of the" exact="infection" post="[63]. Liao et al., analyzing cells from bronchoalveolar lavage"/>
 <result pre="Covid-19, showed that severe disease course was associated with a" exact="prevalence" post="of monocyte-derived macrophages that overwhelmed tissue resident macrophages and"/>
 <result pre="the large majority of infected subjects can recover from the" exact="infection" post="owing to a balanced immune response. In Figure 1a,"/>
 <result pre="of lymphocytes is likely to start some days after virus" exact="infection" post="and to take about a week in normal conditions."/>
 <result pre="conditions. A crucial aspect to contrast the spreading of the" exact="infection" post="is the availability of a large T cell repertoire,"/>
 <result pre="spreading is particularly important, as during the kinetics of the" exact="infection" post="the coronaviruses tend to dampen T-cell response by several"/>
 <result pre="function, tend to develop more severe disease, requiring multiple drug" exact="treatment" post="[72]. This may suggest that B cells may also"/>
 <result pre="same family. For example, subjects who recovered from a first" exact="infection" post="with Dengue virus may get infected again with worse"/>
 <result pre="from Dengue may undergo a severe course from Zika virus" exact="infection" post="and vice versa [76]. The occurrence of ADE has"/>
 <result pre="Liu et al. showed in an animal model of SARS-CoV" exact="infection" post="that the presence of anti-spike IgG actually promoted proinflammatory"/>
 <result pre="courses of disease. Other factors affecting the course of the" exact="infection" post="may include the production of non-neutralizing antibodies enhancing viral"/>
 <result pre="been demonstrated, in fact, that blocking IFN-I signaling in MERS-CoV" exact="infection" post="impairs virus-specific T-cell responses, leading to increased inflammation and"/>
 <result pre="slow immune reaction may not be able to eradicate the" exact="infection" post="in subjects affected with various comorbidities that can reduce"/>
 <result pre="changes typically associated with worsening of disease course. Although direct" exact="infection" post="may account for increased lymphocyte apoptosis, it seems more"/>
 <result pre="swine flu [90] and confirmed in experimental models of viral" exact="infection" post="in mice lacking type I interferon receptor IFNAR [91]."/>
 <result pre="and a trend for higher TNF-Î±. In these patients anti-IL6" exact="treatment" post="with tocilizumab resulted in increased circulating lymphocytes, highlighting the"/>
 <result pre="fatalities, especially when patients cannot endure the challenge of the" exact="infection" post="on vital functions, because of comorbidities (Figure 2). Acute"/>
 <result pre="fungal infections, which can precipitate a fatal course of the" exact="infection" post="[7]. Heart or kidney failure can also occur in"/>
 <result pre="failure [97]. Vasculopathy and coagulopathy are probably related to the" exact="infection" post="of endothelial cells by SARS-CoV-2 [31,98], but it could"/>
 <result pre="of ACE2; this may account for a lower than expected" exact="prevalence" post="of smokers in diseases cohorts, even though the overall"/>
 <result pre="used to speculate on a possible increased susceptibility to SARS-CoV-2" exact="infection" post="in patients under those treatments, or vice versa, if"/>
 <result pre="failed to identify any correlation between ACE inhibitor or ARBs" exact="treatment" post="and infection risk or disease severity. Scientific societies advice"/>
 <result pre="identify any correlation between ACE inhibitor or ARBs treatment and" exact="infection" post="risk or disease severity. Scientific societies advice not to"/>
 <result pre="viral entry into cells [113,114]. However, even antibodies mediating viral" exact="infection" post="can be protective in certain circumstances [115]. Even if"/>
 <result pre="dysregulation of IFN pathways could contribute to lethality from SARS-CoV-2" exact="infection" post="by determining the inability to control viral replication at"/>
 <result pre="dose is a crucial factor influencing the outcome of the" exact="infection" post="from many viruses. High inoculum dose of viruses with"/>
 <result pre="an in vitro model to examine the effects of influenza" exact="infection" post="on DC function, T-cell proliferation occurred at low multiplicities"/>
 <result pre="and CD8 T-mediated cytotoxicity have been associated with unexpected fatal" exact="infection" post="from various viruses, presenting with the clinical picture of"/>
 <result pre="high risk populations is of key relevance to implement stratified" exact="social distancing" post="rules and disease prevention (i.e., vaccine administration) priorities. To"/>
 <result pre="no overt disease could provide guidance for the identification of" exact="treatment" post="targets in humans. One hypothesis is that the bat"/>
 <result pre="system coevolved with viruses mitigating cellular pathways activated by viral" exact="infection" post="to reach a state of reciprocal tolerance. Bats may"/>
 <result pre="a result of these unique adaptations at the cost of" exact="infection" post="persistence and prolonged viral shedding [132], which is probably"/>
 <result pre="a prompt and adequate immune response is crucial to avoid" exact="infection" post="progression [140,141]. All the components of immunity may act"/>
 <result pre="foe: IFNs are necessary in the first phase of the" exact="infection" post="but may become harmful afterwards; tissue macrophages and DCs"/>
 <result pre="neutrophils are needed for viral clearance in animal models of" exact="infection" post="with influenza virus, but are primary players of tissue"/>
 <result pre="trial. Lopinavir/ritonavir is an approved oral combination agent for the" exact="treatment" post="of HIV. The association has been previously used in"/>
 <result pre="in mortality and intubation rates in patients who received this" exact="treatment" post="[142]. The first published randomized trial in Covid-19 was"/>
 <result pre="nucleotide analogue prodrug that inhibits viral RNA polymerases. In vitro" exact="testing" post="of remdesivir has shown a potent activity against SARS-CoV-2"/>
 <result pre="interesting, these data still suggest that the role of antiviral" exact="treatment" post="may be limited, with a greater efficacy possibly to"/>
 <result pre="inhibits viral RNA-dependent RNA polymerase. Favipiravir is approved for the" exact="treatment" post="of influenza virus infections in Japan and China. The"/>
 <result pre="trials are underway. Ribavirin has been empirically included into various" exact="treatment" post="protocols for Covid-19 even though there is little evidence"/>
 <result pre="only at high concentrations. Ribavirin has been used for the" exact="treatment" post="of SARS and MERS, mostly in combination with IFNs."/>
 <result pre="With these premises ribavirin likely has limited value for the" exact="treatment" post="of Covid-19. 6.2. Chloroquine and Hydroxychloroquine Chloroquine and hydroxychloroquine"/>
 <result pre="anti-inflammatory effects possibly due to attenuation of IL6), for the" exact="treatment" post="of Covid-19 has widely spread despite very limited efficacy"/>
 <result pre="criteria were removed from the analysis due to cessation of" exact="treatment" post="as a consequence of worsening illness or medication-related adverse"/>
 <result pre="transfer or death, by means of an inverse probability of" exact="treatment" post="weighting approach, did not find evidence of hydroxychloroquine efficacy"/>
 <result pre="the National Institute of Health expert panel that issued Covid-19" exact="treatment" post="guidelines recommended against the use, outside clinical trials, of"/>
 <result pre="a humanized monoclonal antibody targeting IL-6 receptor, approved for the" exact="treatment" post="of cytokine-release syndrome following chimeric antigen receptor T-cell (CAR-T)"/>
 <result pre="stable respiratory status in 77 patients within 10 days from" exact="treatment" post="start [162]. Several randomized-controlled trials are currently under way"/>
 <result pre="Other anti-cytokine drugs seem to have a rationale for the" exact="treatment" post="of Covid-19 associated inflammation. This is the case of"/>
 <result pre="Covid-19 immunopathogenesis, emapalumab, an anti-IFN-Î³ monoclonal antibody used for the" exact="treatment" post="of hemophagocytic lymphohistiocytosis, has been proposed [167]. Both drugs"/>
 <result pre="In addition, anti-TNF-Î± monoclonal antibodies have been proposed as potential" exact="treatment" post="to prevent progression to needing intensive care in Covid-19"/>
 <result pre="which have also been reported in association with SARS CoV-2" exact="infection" post="[179]. 6.6. Interferons and JAK-Inhibitors Interferons are key molecules"/>
 <result pre="mouse model [65]. IFNs have been proposed as a potential" exact="treatment" post="of Covid-19 for their in vitro and in vivo"/>
 <result pre="Given the previously discussed role of IFN in coronavirus diseases," exact="treatment" post="timing could represent the most determining factor. In mouse"/>
 <result pre="factor. In mouse models, IFN-I administration within 1 day after" exact="infection" post="protected mice from lethal MERS infection, while delayed treatment"/>
 <result pre="after infection protected mice from lethal MERS infection, while delayed" exact="treatment" post="failed to effectively inhibit virus replication, and resulted in"/>
 <result pre="did not require intensive care, and were discharged earlier. Notably," exact="treatment" post="was tolerated in all patients, with no serious adverse"/>
 <result pre="therapy seemed to confer an increased risk of secondary bacterial" exact="infection" post="and mortality [187]. It is noteworthy to report, however,"/>
 <result pre="important than the humoral response, both for recovering from primary" exact="infection" post="and to prevent reinfections. Unlike antibodies, SARS-CoV-specific memory, CD8"/>
 <result pre="Recent observation in agammaglobulinemic patients of spontaneous recovery from SARS-CoV-2" exact="infection" post="supports the hypothesis that T-cell immunity might be more"/>
 <result pre="blocker for the second phase if inflammation persists, with special" exact="treatment" post="such as convalescent plasma, hyperimmune globulins or SARS-CoV-2-specific monoclonal"/>
 <result pre="Infect. Dis.202010.1016/S1473-3099(20)30243-7 5.McCombsA.KadelkaC.A model-based evaluation of the efficacy of COVID-19" exact="social distancing," post="testing and hospital triage policiesmedRxiv202010.1101/2020.04.20.20073213 6.De WitE.van DoremalenN.FalzaranoD.MunsterV.J.SARS and"/>
 <result pre="5.McCombsA.KadelkaC.A model-based evaluation of the efficacy of COVID-19 social distancing," exact="testing" post="and hospital triage policiesmedRxiv202010.1101/2020.04.20.20073213 6.De WitE.van DoremalenN.FalzaranoD.MunsterV.J.SARS and MERS:"/>
 <result pre="InhibitorCell202018127128010.1016/j.cell.2020.02.05232142651 17.JiaH.P.LookD.C.ShiL.HickeyM.PeweL.NetlandJ.FarzanM.Wohlford-LenaneC.PerlmanS.McCrayP.B.Jr.ACE2 receptor expression and severe acute respiratory syndrome coronavirus" exact="infection" post="depend on differentiation of human airway epitheliaJ. Virol.200579146141462110.1128/JVI.79.23.14614-14621.200516282461 18.WrappD.WangN.CorbettK.S.GoldsmithJ.A.HsiehC.L.AbionaO.GrahamB.S.McLellanJ.S.Cryo-EM"/>
 <result pre="of ACE2, the putative receptor of Wuhan 2019-nCovbioRxiv202010.1101/2020.01.26.919985 31.VargaZ.FlammerA.J.SteigerP.HabereckerM.AndermattR.ZinkernagelA.S.MehraM.R.SchuepbachR.A.RuschitzkaF.MochH.Endothelial cell" exact="infection" post="and endotheliitis in COVID-19Lancet202010.1016/S0140-6736(20)30937-5 32.LamersM.M.BeumerJ.van der VaartJ.KnoopsK.PuschhofJ.BreugemT.I.RavelliR.B.G.Paul van SchayckJ.MykytynA.Z.DuimelH.Q.et"/>
 <result pre="al.SARS-CoV-2 productively infects human gut enterocytesScience202010.1126/science.abc1669 33.WangX.ZhouY.JiangN.ZhouQ.MaW.L.Persistence of intestinal SARS-CoV-2" exact="infection" post="in patients with COVID-19 leads to re-admission after pneumonia"/>
 <result pre="49.ChannappanavarR.FehrA.R.ZhengJ.Wohlford-LenaneC.AbrahanteJ.E.MackM.SompallaeR.McCrayP.B.Jr.MeyerholzD.K.PerlmanS.IFN-I response timing relative to virus replication determines MERS coronavirus" exact="infection" post="outcomesJ. Clin. Investig.20191303625363910.1172/JCI126363 50.JingH.SuH.C.New immunodeficiency syndromes that help us"/>
 <result pre="up-regulation in SARS-coronavirus-infected, monocyte-derived human dendritic cellsBlood20051062366237410.1182/blood-2004-10-416615860669 60.Cervantes-BarraganL.ZustR.WeberF.SpiegelM.LangK.S.AkiraS.ThielV.LudewigB.Control of coronavirus" exact="infection" post="through plasmacytoid dendritic-cell-derived type I interferonBlood20071091131113710.1182/blood-2006-05-02377016985170 61.LeggeK.L.BracialeT.J.Accelerated migration of"/>
 <result pre="76.OliveiraR.A.de Oliveira-FilhoE.F.FernandesA.I.BritoC.A.MarquesE.T.TenorioM.C.GilL.H.Previous dengue or Zika virus exposure can drive to" exact="infection" post="enhancement or neutralisation of other flavivirusesMem. Inst. Oswaldo Cruz2019114e19009810.1590/0074-0276019009831411310"/>
 <result pre="Wuhan, ChinaIntensiv. Care Med.20201310.1007/s00134-020-05991-x 88.WynantsL.Van CalsterB.BontenM.M.J.CollinsG.S.DebrayT.P.A.De VosM.HallerM.C.HeinzeG.MoonsK.G.M.RileyR.D.et al.Prediction models for" exact="diagnosis" post="and prognosis of covid-19 infection: Systematic review and critical"/>
 <result pre="in identifying coronavirus-associated illnessesJ. Med. Virol.20209251251710.1002/jmv.2571532073157 113.LeeD.W.GardnerR.PorterD.L.LouisC.U.AhmedN.JensenM.GruppS.A.MackallC.L.Current concepts in the" exact="diagnosis" post="and management of cytokine release syndromeBlood201412418819510.1182/blood-2014-05-55272924876563 114.WanY.ShangJ.SunS.TaiW.ChenJ.GengQ.HeL.ChenY.WuJ.ShiZ.et al.Molecular Mechanism"/>
 <result pre="viral reservoir hostNat. Microbiol.2019478979910.1038/s41564-019-0371-330804542 136.RenR.WuS.CaiJ.YangY.RenX.FengY.ChenL.QinB.XuC.YangH.et al.The H7N9 influenza A virus" exact="infection" post="results in lethal inflammation in the mammalian host via"/>
 <result pre="mammalian host via the NLRP3-caspase-1 inflammasomeSci. Rep.20177762510.1038/s41598-017-07384-528790324 137.WangW.LiG.DeW.LuoZ.PanP.TianM.WangY.XiaoF.LiA.WuK.et al.Zika virus" exact="infection" post="induces host inflammatory responses by facilitating NLRP3 inflammasome assembly"/>
 <result pre="role of the NLRP3 inflammasome during pathogenic influenza A virus" exact="infection" post="via temporal inhibitionSci. Rep.201662791210.1038/srep2791227283237 140.ZouL.RuanF.HuangM.LiangL.HuangH.HongZ.YuJ.KangM.SongY.XiaJ.et al.SARS-CoV-2 Viral Load in"/>
 <result pre="pneumonia: A prospective studyLancet20033611767177210.1016/S0140-6736(03)13412-512781535 142.ChuC.M.ChengV.C.HungI.F.WongM.M.ChanK.H.ChanK.S.KaoR.Y.PoonL.L.WongC.L.GuanY.et al.Role of lopinavir/ritonavir in the" exact="treatment" post="of SARS: Initial virological and clinical findingsThorax20045925225610.1136/thorax.2003.01265814985565 143.CaoB.WangY.WenD.LiuW.WangJ.FanG.RuanL.SongB.CaiY.WeiM.et al.A"/>
 <result pre="versus Arbidol for COVID-19: A Randomized Clinical TrialmedRxiv202010.1101/2020.03.17.20037432 149.KhaliliJ.S.ZhuH.MakA.YanY.ZhuY.Novel coronavirus" exact="treatment" post="with ribavirin: Groundwork for evaluation concerning COVID-19J. Med. Virol.202010.1002/jmv.2579832227493"/>
 <result pre="for evaluation concerning COVID-19J. Med. Virol.202010.1002/jmv.2579832227493 150.StockmanL.J.BellamyR.GarnerP.SARS: Systematic review of" exact="treatment" post="effectsPLoS Med.20063e34310.1371/journal.pmed.003034316968120 151.LiuJ.CaoR.XuM.WangX.ZhangH.HuH.LiY.HuZ.WuZ.WangM.Hydroxychloroquine, a less toxic derivative of chloroquine,"/>
 <result pre="less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2" exact="infection" post="in vitroCell Discov.2020610.1038/s41421-020-0156-0 152.GautretP.LagierJ.C.ParolaP.HoangV.T.MeddebL.MailheM.DoudierB.CourjonJ.GiordanengoV.VieiraV.E.et al.Hydroxychloroquine and azithromycin as a"/>
 <result pre="infection in vitroCell Discov.2020610.1038/s41421-020-0156-0 152.GautretP.LagierJ.C.ParolaP.HoangV.T.MeddebL.MailheM.DoudierB.CourjonJ.GiordanengoV.VieiraV.E.et al.Hydroxychloroquine and azithromycin as a" exact="treatment" post="of COVID-19: Results of an open-label non-randomized clinical trialInt."/>
 <result pre="of clinical efficacy of hydroxychloroquine in patients hospitalized for COVID-19" exact="infection" post="with oxygen requirement: Results of a study using routinely"/>
 <result pre="Young Adults with B-Cell 4Lymphoblastic LeukemiaN. Engl. J. Med.201837843944810.1056/NEJMoa170986629385370 160.LuoP.LiuY.QiuL.LiuX.LiuD.LiJ.Tocilizumab" exact="treatment" post="in COVID-19: A single center experienceJ. Med. Virol.202010.1002/jmv.25801 161.Di"/>
 <result pre="Patients with SARS-CoV-2 InfectionJ. Med. Virol.202010.1002/jmv.25897 162.ToniatiP.PivaS.CattaliniM.GarrafaE.RegolaF.CastelliF.FranceschiniF.FocÃ E.AndreoliL.LatronicoN.Tocilizumab for the" exact="treatment" post="of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute"/>
 <result pre="on pathogenesis of SARS coronavirusBMC Syst. Biol.2016109310.1186/s12918-016-0336-627663205 172.HungI.F.ToK.K.LeeC.K.LeeK.L.ChanK.YanW.W.LiuR.WattC.L.ChanW.M.LaiK.Y.et al.Convalescent plasma" exact="treatment" post="reduced mortality in patients with severe pandemic influenza A"/>
 <result pre="al.The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the" exact="treatment" post="of severe acute respiratory infections of viral etiology: A"/>
 <result pre="Syndrome: A Multicenter Observational StudyClin. Infect. Dis.2020701837184410.1093/cid/ciz54431925415 181.RichardsonP.GriffinI.TuckerC.SmithD.OechsleO.PhelanA.StebbingJ.Baricitinib as potential" exact="treatment" post="for 2019-nCoV acute respiratory diseaseLancet2020395e30e3110.1016/S0140-6736(20)30304-432032529 182.CantiniF.NiccoliL.MatarreseD.NicastriE.StobbioneP.GolettiD.Baricitinib therapy in COVID-19:"/>
 <result pre="syndromeAm. J. Respir. Crit. Care Med.20031681449145610.1164/rccm.200306-766OC12947028 185.SoL.K.LauA.C.YamL.Y.CheungT.M.PoonE.YungR.W.YuenK.Y.Development of a standard" exact="treatment" post="protocol for severe acute respiratory syndromeLancet20033611615161710.1016/S0140-6736(03)13265-512747883 186.SungJ.J.WuA.JoyntG.M.YuenK.Y.LeeN.ChanP.K.CockramC.S.AhujaA.T.YuL.M.WongV.W.et al.Severe acute"/>
 <result pre="acute respiratory syndromeLancet20033611615161710.1016/S0140-6736(03)13265-512747883 186.SungJ.J.WuA.JoyntG.M.YuenK.Y.LeeN.ChanP.K.CockramC.S.AhujaA.T.YuL.M.WongV.W.et al.Severe acute respiratory syndrome: Report of" exact="treatment" post="and outcome after a major outbreakThorax20045941442010.1136/thx.2003.01407615115870 187.RodrigoC.Leonardi-BeeJ.Nguyen-Van-TamJ.LimW.S.Corticosteroids as adjunctive"/>
 <result pre="after a major outbreakThorax20045941442010.1136/thx.2003.01407615115870 187.RodrigoC.Leonardi-BeeJ.Nguyen-Van-TamJ.LimW.S.Corticosteroids as adjunctive therapy in the" exact="treatment" post="of influenzaCochrane Database Syst. Rev.2016310.1002/14651858.CD010406.pub2 188.WuC.ChenX.CaiY.XiaJ.ZhouX.XuS.HuangH.ZhangL.ZhouX.DuC.et al.Risk Factors Associated"/>
</results>
